Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

• Status: Completed
• Trial end date: 2016-11-25
• Target enrollment: 0
• Participant gender: All

Summary

This is a study to assess the safety and efficacy of the addition of ipragliflozin once daily in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and exercise therapy. The primary hypothesis for this study is that the addition of ipragliflozin compared with placebo provides greater reduction in hemoglobin A1C (HbA1c) as assessed by change from baseline at Week 24.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Ipragliflozin; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Type 2 diabetes mellitus

• Inadequate glycemic control on diet/exercise therapy and sitagliptin monotherapy

• HbA1c ≥7.0% and ≤10.0% before study start

Exclusion Criteria:

• History of Type 1 diabetes mellitus or a history of ketoacidosis

• History of any of the following medications: thiazolidinediones (TZD) and/or insulin within 12 weeks prior to study participation and sodium glucose cotransporter 2 (SGLT2) inhibitors anytime

• Currently has a urinary tract infection or genital infection with subjective symptom